Turbo CAR T-Cell Product Granted Orphan Drug Designation

ALLO-605, a Turbo chimeric antigen receptor (CAR) T-cell product, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM), according to a company press release.

ALLO-605 is a proprietary, next-generation platform technology based on a programmable cytokine signaling, designed to control T-cell exhaustion and to improve T-cell function and potency. These properties may enable CAR-T products to succeed in more difficult-to-treat hematologic malignancies and solid tumors.

The FDA previously granted the therapy Fast Track Designation based on the potential for the product to address an unmet need for patients with relapsed or refractory MM.

Preclinical results of ALLO-605 were presented at the 2020 ASH Annual Meeting. A phase I study evaluating ALLO-605 is currently underway.

Source: Allogene Therapeutics Press Release, April 2022